🦠 Döhler begins commercial production of Superbrewed’s postbiotic protein in Europe, with US product launches planned for later this year

SB1, a high-protein postbiotic ingredient produced from a non-GMO bacterium grown anaerobically, contains 88%+ protein with a neutral taste and colour, strong pH and heat stability, and good emulsification properties.

It received an FDA GRAS “no questions” letter in 2024 and is drawing interest across protein beverages, snacks, and yogurts, with Fonterra and Bel Brands among existing partners.

Unlike companies that discard microbial biomass after extracting a target compound, Superbrewed harvests the whole bacterium as a food ingredient, with butyric acid as a co-product.

The company claims SB1 can deliver 35g of fully digestible protein in five ounces of water with good texture, something dairy struggles to achieve and plant proteins cannot match without turning viscous.

The production milestone follows a full tech transfer into Döhler's Netherlands facility, with spray drying in Germany, using a partner-led, capital-efficient model rather than asset-heavy scale-up.

Döhler Ventures has also made an undisclosed investment in Superbrewed to support broader commercialisation in 2027.